Two Sigma Investments LP Has $233,000 Stock Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Two Sigma Investments LP boosted its position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 44.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 136,920 shares of the company's stock after acquiring an additional 41,836 shares during the period. Two Sigma Investments LP owned approximately 0.33% of Vigil Neuroscience worth $233,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Blair William & Co. IL bought a new stake in shares of Vigil Neuroscience in the 4th quarter valued at approximately $551,000. Renaissance Technologies LLC grew its stake in shares of Vigil Neuroscience by 698.5% in the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company's stock valued at $624,000 after purchasing an additional 321,300 shares during the period. Trustees of Columbia University in the City of New York bought a new stake in shares of Vigil Neuroscience in the 4th quarter valued at approximately $328,000. 683 Capital Management LLC grew its stake in shares of Vigil Neuroscience by 14.8% in the 4th quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company's stock valued at $2,380,000 after purchasing an additional 180,420 shares during the period. Finally, Boothbay Fund Management LLC bought a new stake in shares of Vigil Neuroscience in the 4th quarter valued at approximately $249,000. 83.64% of the stock is currently owned by institutional investors.

Vigil Neuroscience Stock Down 0.1%

NASDAQ:VIGL traded down $0.01 during trading hours on Friday, hitting $7.86. 3,558,818 shares of the stock were exchanged, compared to its average volume of 721,446. The company's 50 day moving average is $4.03 and its two-hundred day moving average is $2.79. Vigil Neuroscience, Inc. has a twelve month low of $1.31 and a twelve month high of $7.95. The company has a market capitalization of $366.84 million, a P/E ratio of -3.82 and a beta of 3.43.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. On average, equities research analysts expect that Vigil Neuroscience, Inc. will post -2.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on VIGL. Stifel Nicolaus lowered Vigil Neuroscience from a "buy" rating to a "hold" rating and lowered their price objective for the company from $11.00 to $8.00 in a research note on Wednesday, May 28th. HC Wainwright lowered Vigil Neuroscience from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $14.00 to $8.00 in a research report on Tuesday, May 27th. Citizens Jmp lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Guggenheim set a $8.00 price target on Vigil Neuroscience and gave the stock a "neutral" rating in a research report on Thursday, May 22nd. Finally, JMP Securities restated a "market perform" rating on shares of Vigil Neuroscience in a research report on Thursday, May 22nd. Ten research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $10.80.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.